Schwannoma MRI: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 5: Line 5:
==Overview==
==Overview==


Schwannomas appear on T1 as isointense or hypointense, T1 C+ (Gd) intense enhancement,T2- heterogeneously hyperintense (Antoni A: relatively low, Antoni B: high), cystic degenerative areas may be present, especially in larger tumors, T2- larger tumors often have areas of hemosiderin. Signs can also be useful in diagnosing such as split-fat sign: thin peripheral rim of fat best seen on planes along long axis of the lesion in non-fat-suppressed sequences, target sign: peripheral high T2 signal, central low signal rarely seen intracranially, fascicular sign: multiple small ring-like structures.
==MRI==
==MRI==



Revision as of 23:20, 29 October 2019

Schwannoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Schwannoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Schwannoma MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Schwannoma MRI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Schwannoma MRI

CDC on Schwannoma MRI

Schwannoma MRI in the news

Blogs on Schwannoma MRI

Directions to Hospitals Treating Schwannoma

Risk calculators and risk factors for Schwannoma MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Maneesha Nandimandalam, M.B.B.S.[2]

Overview

Schwannomas appear on T1 as isointense or hypointense, T1 C+ (Gd) intense enhancement,T2- heterogeneously hyperintense (Antoni A: relatively low, Antoni B: high), cystic degenerative areas may be present, especially in larger tumors, T2- larger tumors often have areas of hemosiderin. Signs can also be useful in diagnosing such as split-fat sign: thin peripheral rim of fat best seen on planes along long axis of the lesion in non-fat-suppressed sequences, target sign: peripheral high T2 signal, central low signal rarely seen intracranially, fascicular sign: multiple small ring-like structures.

MRI

Schwannomas have fairly predictable signal characteristics [1] [2][3][4] [5][6] :

  • T1: isointense or hypointense
  • T1 C+ (Gd): intense enhancement
  • T2: heterogeneously hyperintense (Antoni A: relatively low, Antoni B: high)
    • cystic degenerative areas may be present, especially in larger tumors
  • T2*: larger tumors often have areas of hemosiderin

A number of signs can also be useful:

  • split-fat sign: thin peripheral rim of fat best seen on planes along long axis of the lesion in non-fat-suppressed sequences
  • target sign
    • peripheral high T2 signal
    • central low signal
    • rarely seen intracranially 7
  • fascicular sign: multiple small ring-like structures

MR image of left sided vestibular schwannoma. Yellow dotted line is border between intra- and extrameatal portion of the tumour. Size quantified as the largest diameter measurable in the extrameatal portion (red line), Kleijwegt MC, van der Mey AG, Wiggers-deBruine FT, Malessy MJ, van Osch MJ. Perfusion magnetic resonance imaging provides additional information as compared to anatomical imaging for decision-making in vestibular schwannoma. Eur J Radiol Open. 2016;3:127–133. Published 2016 Jun 15. doi:10.1016/j.ejro.2016.05.005,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919314/

References

  1. Rosahl S, Bohr C, Lell M, Hamm K, Iro H (2017). "Diagnostics and therapy of vestibular schwannomas - an interdisciplinary challenge". GMS Curr Top Otorhinolaryngol Head Neck Surg. 16: Doc03. doi:10.3205/cto000142. PMC 5738934. PMID 29279723.
  2. Zou J, Hirvonen T (2017). ""Wait and scan" management of patients with vestibular schwannoma and the relevance of non-contrast MRI in the follow-up". J Otol. 12 (4): 174–184. doi:10.1016/j.joto.2017.08.002. PMC 6002632. PMID 29937853.
  3. Jeong KH, Choi JW, Shin JE, Kim CH (2016). "Abnormal Magnetic Resonance Imaging Findings in Patients With Sudden Sensorineural Hearing Loss: Vestibular Schwannoma as the Most Common Cause of MRI Abnormality". Medicine (Baltimore). 95 (17): e3557. doi:10.1097/MD.0000000000003557. PMC 4998729. PMID 27124066.
  4. Kleijwegt MC, van der Mey AG, Wiggers-deBruine FT, Malessy MJ, van Osch MJ (2016). "Perfusion magnetic resonance imaging provides additional information as compared to anatomical imaging for decision-making in vestibular schwannoma". Eur J Radiol Open. 3: 127–33. doi:10.1016/j.ejro.2016.05.005. PMC 4919314. PMID 27366777.
  5. Lin EP, Crane BT (2017). "The Management and Imaging of Vestibular Schwannomas". AJNR Am J Neuroradiol. 38 (11): 2034–2043. doi:10.3174/ajnr.A5213. PMC 5690865. PMID 28546250.
  6. Singh K, Singh MP, Thukral C, Rao K, Singh K, Singh A (March 2015). "Role of magnetic resonance imaging in evaluation of cerebellopontine angle schwannomas". Indian J Otolaryngol Head Neck Surg. 67 (1): 21–7. doi:10.1007/s12070-014-0736-0. PMC 4298582. PMID 25621227.

Template:WH Template:WS